HighMark Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

HighMark Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.29K	Hold	75	–	–	﹤0.01%	407
2026 Q1	$4.24K	Hold	75	–	–	﹤0.01%	399
2025 Q4	$4.46K	Hold	75	–	–	﹤0.01%	420
2025 Q3	$4.06K	Hold	75	–	–	﹤0.01%	422
2025 Q2	$4.12K	Hold	75	–	–	﹤0.01%	419
2025 Q1	$5.3K	Hold	75	–	–	﹤0.01%	366
2024 Q4	$4.93K	Hold	75	–	–	﹤0.01%	384
2024 Q3	$5.27K	Hold	75	–	–	﹤0.01%	395
2024 Q2	$6.17K	Hold	75	–	–	﹤0.01%	355
2024 Q1	$6.55K	Hold	75	–	–	﹤0.01%	347
2023 Q4	$7.23K	Hold	75	–	–	0.01%	315
2023 Q3	$6.64K	Sell	75 -75	-50%	-$6.67K	0.01%	314
2023 Q2	$13K	Hold	150	–	–	0.01%	228
2023 Q1	$14.6K	Hold	150	–	–	0.01%	244
2022 Q4	$15.5K	Hold	150	–	–	0.01%	195
2022 Q3	$13K	Hold	150	–	–	0.01%	200
2022 Q2	$12K	Hold	150	–	–	0.01%	219
2022 Q1	$12K	Hold	150	–	–	0.01%	236
2021 Q4	$13K	Sell	150 -152	-50%	-$12.5K	0.01%	223
2021 Q3	$23K	Buy	+302	New	+$23.8K	0.02%	170
2020 Q3	–	Sell	-69	Closed	-$9K	–	447
2020 Q2	$9K	Buy	+69	New	+$6.86K	0.01%	212

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

HighMark Wealth Management's BMRN Position: Q2 2026 in Review

HighMark Wealth Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 75 shares worth $4.29K. The position accounts for ﹤0.01% of the portfolio, ranked #407.

HighMark Wealth Management first reported a position in BMRN in Q2 2020 and has held it in 21 quarters since. The position peaked at $23K in Q3 2021. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

HighMark Wealth Management held 75 shares of BioMarin Pharmaceuticals worth $4.29K as of Q2 2026.
HighMark Wealth Management left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of HighMark Wealth Management's portfolio in Q2 2026, its #407 holding.
HighMark Wealth Management first reported a position in BioMarin Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
HighMark Wealth Management's BioMarin Pharmaceuticals position peaked at $23K in Q3 2021.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.